Genelux (GNLX) Cash from Operations (2022 - 2026)
Genelux (GNLX) recorded quarterly Cash from Operations of 6059000.0 in Q1 2026, up 2.27% quarter-over-quarter from 6200000.0 in Q4 2025, and down 11.48% on a YoY basis from 6844869.05 in Q1 2025.
Genelux (GNLX) Cash from Operations (2022 - 2026) Analysis & Trends
Genelux's Cash from Operations history runs 5 years deep, the most recent figure standing at 6059000.0 for Q1 2026.
- In Q1 2026, Cash from Operations fell 11.48% year-over-year to 6059000.0; the TTM figure through Mar 2026 stood at 25924000.0 (down 16.2% YoY), while the FY2025 annual figure was 25300000.0, down 19.18% from the prior year.
- Cash from Operations was 6059000.0 for Q1 2026 at Genelux, up from 6200000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 2825000.0 in Q1 2022 to a low of 7065000.0 in Q2 2025.
- Historically, Cash from Operations has averaged 4770333.33 across 5 years, with a median of 5435000.0 in 2025.
- The sharpest annual moves came in 2023 and 2024: Cash from Operations slumped 355.2% in 2023, then surged 37.74% in 2024.
- A 5-year view of Cash from Operations shows it stood at 1518000.0 in 2022, then slumped by 355.2% to 6910000.0 in 2023, then soared by 37.74% to 4302000.0 in 2024, then tumbled by 44.12% to 6200000.0 in 2025, then climbed by 2.27% to 6059000.0 in 2026.
- The last three Cash from Operations figures came in at 6059000.0 (Q1 2026), 6200000.0 (Q4 2025), and 6600000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.49 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | - |
| 10 | Genelux | 129.36 Mn | 129.36 Mn | - | -6.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -6.06 Mn |
| Mar 31, 2026 | -6.06 Mn |
| Dec 31, 2025 | -6.20 Mn |
| Dec 31, 2025 | -6.20 Mn |
| Sep 30, 2025 | -6.60 Mn |
| Sep 30, 2025 | -6.60 Mn |
| Jun 30, 2025 | -7.07 Mn |
| Jun 30, 2025 | -7.07 Mn |
| Mar 31, 2025 | -5.44 Mn |
| Mar 31, 2025 | -5.44 Mn |
| Dec 31, 2024 | -4.30 Mn |
| Dec 31, 2024 | -4.30 Mn |
| Sep 30, 2024 | -5.75 Mn |
| Sep 30, 2024 | -5.75 Mn |
| Jun 30, 2024 | -6.82 Mn |
| Jun 30, 2024 | -6.82 Mn |
| Mar 31, 2024 | -4.35 Mn |
| Mar 31, 2024 | -4.35 Mn |
| Dec 31, 2023 | -6.91 Mn |
| Dec 31, 2023 | -6.91 Mn |